McKinsey Settles Opioid Case for $650 Million
TL;DR Summary
McKinsey & Company has agreed to pay $650 million to settle criminal charges related to its role in promoting OxyContin sales for Purdue Pharma, contributing to the opioid epidemic. The firm will cease any work related to controlled substances and will not contest the charges, which include conspiracy to defraud the U.S. and document destruction. This settlement follows a previous $573 million agreement with state attorneys general over similar allegations.
- McKinsey to pay $650 million over role in OxyContin epidemic ABC News
- McKinsey to Pay $650 Million in Opioid Settlement With Justice Department The New York Times
- McKinsey to pay $650 million after advising opioid maker on how to 'turbocharge' sales USA TODAY
- Consulting firm McKinsey to pay $650 million to end opioid criminal probe The Washington Post
- McKinsey & Company to pay $650 million to settle opioid consulting probe, ex-partner to plead guilty CNBC
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
2 min
vs 2 min read
Condensed
82%
383 → 70 words
Want the full story? Read the original article
Read on ABC News